Login to Your Account



Financings Roundup

Vivus Plays for Time; Enters $110M Capped Royalty Deal

By Catherine Shaffer
Staff Writer

Wednesday, March 27, 2013
A synthetic capped royalty financing of $110 million will help Vivus Inc., of Mountain View, Calif., buy time while it awaits a decision on its risk evaluation and mitigation stragegy (REMS) modification amendment and a more opportune time for an equity financing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription